Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003720 · ClinicalTrials.gov registry record · Phase 1
SU5416 in Treating Patients With AIDS-Related Kaposi's Sarcoma
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00003720 is a Phase 1 study that has completed, run by Pfizer.
The verdict
NCT00003720, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: SU5416 may stop the growth of Kaposi's sarcoma by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the effectiveness of SU5416 in treating patients who have AIDS-related Kaposi's sarcoma.
Interventions
- DRUG semaxanib
Trial Details
| Field | Value |
|---|---|
| Start Date | 1998-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003720
The ClinicalTrials.gov registry entry for NCT00003720 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which semaxanib is the first listed.
NCT00003720 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003720 about?
NCT00003720 is a clinical study titled "SU5416 in Treating Patients With AIDS-Related Kaposi's Sarcoma". RATIONALE: SU5416 may stop the growth of Kaposi's sarcoma by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the effectiveness of SU5416 in treating patients who have AIDS-related Kaposi's sarcoma.
What is the current status of trial NCT00003720?
This trial is currently completed. It is a Phase 1 study. The study started on 1998-07.
What interventions are being tested in trial NCT00003720?
The interventions under investigation include: semaxanib (DRUG).
Who is sponsoring clinical trial NCT00003720?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.